慢性肾脏病患者动脉粥样硬化性心血管疾病风险预测模型:CRIC研究
在CRIC研究中,对2604例无自报心血管疾病的CKD患者开发并验证10年ASCVD风险预测模型,ASCVD定义为首次发生经判定的致死性或非致死性卒中或心肌梗死。CRIC临床变量模型AUC为0.760(95%CI 0.678-0.851),生物标志物增强模型AUC为0.771(95%CI 0.674-0.853),均优于汇总队列方程(AUC=0.730),且校准良好、改善无事件重分类。
要点
- CRIC临床变量模型AUC 0.760(95%CI 0.678-0.851),优于汇总队列方程AUC 0.730。
- CRIC生物标志物增强模型AUC 0.771(95%CI 0.674-0.853),显著高于临床模型(P=0.001)。
- 两模型校准良好,无事件重分类改善分别为6.6%(95%CI 3.7%-9.6%)和10.0%(95%CI 6.8%-13.3%)。
核心结论
- 在CKD患者中开发的10年ASCVD风险预测模型(含新型肾脏和心脏生物标志物)表现优于仅使用传统危险因素的通用人群方程。
研究设计与样本
- 在慢性肾功能不全队列(CRIC)研究中,纳入无自报心血管疾病的CKD患者,开发并验证10年ASCVD风险预测模型。
- ASCVD定义为首次发生经判定的致死性和非致死性卒中或心肌梗死。
- 模型使用临床可用变量和新型生物标志物,基于判别力、校准和净重分类改善评估模型表现。
- 分析纳入2604例参与者(平均年龄55.8岁;52.0%为男性),其中252例在基线后10年内发生ASCVD。
主要发现
- 与美国心脏病学会/美国心脏协会汇总队列方程(AUC=0.730)相比,在CRIC样本内估计系数的模型判别力更高(P=0.03),AUC为0.736(95%CI 0.649-0.826)。
- 使用临床可用变量开发的CRIC模型AUC为0.760(95%CI 0.678-0.851)。
- CRIC生物标志物增强模型AUC为0.771(95%CI 0.674-0.853),显著高于临床模型(P=0.001)。
- 临床模型和生物标志物增强模型均校准良好,与汇总队列方程相比改善无事件重分类,分别为6.6%(95%CI 3.7%-9.6%)和10.0%(95%CI 6.8%-13.3%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with CKD may be at high risk for atherosclerotic cardiovascular disease (ASCVD). However, there are no ASCVD risk prediction models developed in CKD populations to inform clinical care and prevention. METHODS: We developed and validated 10-year ASCVD risk prediction models in patients with CKD that included participants without self-reported cardiovascular disease from the Chronic Renal Insufficiency Cohort (CRIC) study. ASCVD was defined as the first occurrence of adjudicated fatal and nonfatal stroke or myocardial infarction. Our models used clinically available variables and novel biomarkers. Model performance was evaluated based on discrimination, calibration, and net reclassification improvement. RESULTS: Of 2604 participants (mean age 55.8 years; 52.0% male) included in the analyses, 252 had incident ASCVD within 10 years of baseline. Compared with the American College of Cardiology/American Heart Association pooled cohort equations (area under the receiver operating characteristic curve [AUC]=0.730), a model with coefficients estimated within the CRIC sample had higher discrimination (P=0.03), achieving an AUC of 0.736 (95% confidence interval [CI], 0.649 to 0.826). The CRIC model developed using clinically available variables had an AUC of 0.760 (95% CI, 0.678 to 0.851). The CRIC biomarker-enriched model had an AUC of 0.771 (95% CI, 0.674 to 0.853), which was significantly higher than the clinical model (P=0.001). Both the clinical and biomarker-enriched models were well-calibrated and improved reclassification of nonevents compared with the pooled cohort equations (6.6%; 95% CI, 3.7% to 9.6% and 10.0%; 95% CI, 6.8% to 13.3%, respectively). CONCLUSIONS: The 10-year ASCVD risk prediction models developed in patients with CKD, including novel kidney and cardiac biomarkers, performed better than equations developed for the general population using only traditional risk factors.
引用
- Bundy JD, Rahman M, Matsushita K, et al. Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study. J Am Soc Nephrol. 2022. PMID: 35145041. doi:10.1681/ASN.2021060747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。